Researchers Push FDA To Raise Standards For Metal-On-Metal Hips

Flaws in the 510(k) process prevented FDA from noticing high metal-on-metal revision rates, researchers write in the New England Journal of Medicine. Their argument is based on a predicate “ancestry” analysis of DePuy’s recalled ASR hip system.

Researchers pressed FDA to start requiring PMAs for metal-on-metal hips in a Jan. 10 piece in the New England Journal of Medicine.

Metal-on-metal hips have been the subject of substantial international scrutiny in recent years since global registries have shown that patients receiving the devices require revision surgery much more frequently than previously expected. (See Also see "Metal-On-Metal Hips Get Failing Grade In New Registry Analysis" - Medtech Insight, 19 March, 2012.

More from Regulation

More from Policy & Regulation

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By 

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.